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Abstract
Background: Pharmacological treatment for osteoarthritis (OA) can be divided into two groups:
symptom-modifying drugs and disease-modifying drugs. Symptom-modifying drugs are currently the
prescription of choice for patients with OA, as disease-modifying drugs are not yet available in usual
care. However, there has recently been a lot of debate about glucosamine sulphate (GS), a
biological agent that is thought to have both symptom-modifying and disease-modifying properties.
This assumption has yet to be proved.
The objective of this article is to present the design of a blind randomised clinical trial that examines
the long-term symptom-modifying and disease-modifying effectiveness of GS in patients with hip
OA. This trial is ongoing and will finish in March 2006.
Methods/design: Patients with hip OA meeting the ACR-criteria are randomly allocated to either
1500 mg of oral GS or placebo for the duration of two years. The primary outcome measures,
which are joint space narrowing (JSN), and change in the pain and function score of the Western
Ontario McMaster Universities Osteoarthritis index (WOMAC), are determined at baseline and
after two years of follow-up during the final assessment. Intermediate measures at three-month
intervals throughout the trial are used to study secondary outcome measures. Secondary outcome
measures are changes in WOMAC stiffness score, quality of life, medical consumption, side effects
and differences in biomarker CTX-II.
Background
Pharmacological treatment for osteoarthritis (OA) can be
divided into two groups: symptom-modifying drugs and
disease-modifying drugs [1]. Symptom-modifying drugs
are at present the prescription of choice for patients with
OA. Drugs in this group are: simple analgesics (such as
acetaminophen) and non-steroidal anti-inflammatory
drugs (NSAIDs). Both acetaminophen and NSAIDs are
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stages of the disease NSAIDs are more effective, however,
they are also the cause of serious side effects [2].
Disease-modifying drugs (i.e. drugs which alter disease
progression) are not yet available in usual care. Although
there has recently been a lot of debate about some biolog-
ical agents that are thought to have both symptom-modi-
fying and disease-modifying properties, results from
previous trials have not been convincing. Of these biolog-
ical agents, glucosamine sulphate seems to be the most
promising.
Glucosamine sulphate (GS) has been shown to be an
effective symptom-modifying agent, with effect sizes rang-
ing from moderate to high [3,4]. In four trials that com-
pared GS and NSAIDs, GS was found to be as effective as,
or slightly more effective than NSAIDs [4]. Together with
the fact that no serious adverse events have been reported
concerning GS [3,4] this implies that GS may be a good
alternative to NSAIDs. However, due to publication bias
and due to quality issues in the trials studying GS, it may
well be that reported effect sizes are exaggerated. A more
recent trial studying the effect of GS did not find a differ-
ence between GS and placebo [5]. Also, several other
uncertainties exist concerning the symptom-modifying
properties of GS. For example, most trials were only of
short-term duration (e.g. mean 6.25 weeks [4]) and it is
therefore not possible to draw conclusions about the
long-term efficacy. Another problem is that the mecha-
nism behind the improvement of symptoms due to GS is
not known. If GS directly influences the remaining carti-
lage, it would seem plausible that the symptomatic effect
is greater in people with mild to moderate OA than in
people with more severe OA, because there is more carti-
lage remaining in the first group. However, this possible
difference in effect between different stages of OA has not
been tested yet in a randomised clinical trial (RCT). These
uncertainties make further study into the magnitude of
long-term symptom-modifying effects in different stages
of the disease justified.
Concerning disease-modifying effects, two recent long-
term (three years) trials in patients with knee OA did
report some evidence that GS affected the progression of
OA [6,7]. Progressive joint space narrowing in the narrow-
est medial compartment of the tibiofemoral joint was
used to define progression of knee OA (as recommended
by a task force of the OA research society [8]). Whereas
joint space narrowing (JSN), had significantly progressed
in the placebo groups, it had not in the groups that were
taking GS. This implies that daily intake of GS acted
against progression of OA. However, these results are con-
troversial, because both trials lacked appropriate and
standardised protocols for taking radiographs. Although it
is not likely that this influenced the results much [9], it is
necessary to reproduce them in a study with well-stand-
ardised protocols. These two long-term trials both looked
at the effect of GS on knee OA, no trial has been or is being
performed yet that looks at its effect on hip OA.
Based on the above, we designed a long-term trial to
answer our main question: Does glucosamine sulphate
favourably modify progression of osteoarthritis? Because
there still is uncertainty about the symptom-modifying
properties of GS we will also try to answer three secondary
questions: Does GS have the same effects in all stages of
OA? What is the long-term cost-effectiveness of addition
of GS to usual care? And, does GS prevent the onset or
progression of OA in the contralateral hip joint? Addi-
tional to these clinical questions, the data will be used to
look at changes on cell-level caused by GS to learn more
about its possible mechanisms of action. All results
derived from this trial will be published using our Interna-
tional Standardised Randomised Controlled Trial
Number (ISRCTN).
In this article we will present the detailed protocol of the
trial. This trial is ongoing; at the moment all patients are
included and have passed the first 9 months of the follow-
up period.
Methods/design
Study design
This study is a randomised, blinded, placebo-controlled
trial. All actors in this trial, who may cause bias, are
blinded to treatment allocation: the patient, who is the
assessor of the symptomatic outcomes, the researcher,
who is the assessor of the objective outcomes, and the car-
egiver. The analyses will also be performed blind. The
study design was approved by the Medical Ethics Com-
mittee at the Erasmus MC – university medical centre Rot-
terdam. All patients gave written informed consent.
Patient selection
General practitioners in the Rotterdam area agreed to
search their electronic medical record for patients diag-
nosed with hip OA and for patients with symptoms asso-
ciated with hip OA (i.e. persistent hip pain in
combination with NSAID use). These patients are con-
tacted by their general practitioner and informed about
the trial. For more information, patients can forward their
contact details to the researchers. These patients then
receive an extensive information folder containing all the
information needed to make an informed decision about
participation in the study. This folder has been reviewed
and approved by the medical ethics committee.
The information folder also contains an informed consent
form, which patients need to fill out if they want toPage 2 of 7
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informed consent are contacted by phone for a prelimi-
nary check of the inclusion and exclusion criteria. People
meeting these criteria are invited to the research centre of
Erasmus MC for a baseline-measurement, during which
the criteria can be checked more precisely.
In- and exclusion criteria
Patients are eligible for inclusion when they meet one of
the ACR criteria for hip OA [10]. Patients that have already
undergone hip replacement surgery or those on the wait-
ing list for joint replacement are not included in the study.
Neither eligible patients with a Kellgren & Lawrence (K-L)
score of 4 [11], nor people with renal and/or hepatic dis-
ease, diabetes mellitus or a disabling co-morbidity are
included. Finally, patients unable to understand Dutch
questionnaires are excluded from participation.
Sample size
The sample size was calculated primarily to detect clini-
cally relevant differences in radiological progression of the
affected joints between the two groups (treatment and
placebo) after two years of follow up. To detect a differ-
ence of 0.25 mm in radiological progression (SD 0.5)
between the intervention and placebo groups (power
80%, alpha 5%, one-tailed testing) after two years of fol-
low-up, 63 patients with hip osteoarthritis are needed per
group. These calculations are based on an average change
of 0.33 mm in joint space (SD 0.5) during one year of fol-
low-up of patients with hip osteoarthritis [12].
Fewer patients are needed to detect relevant clinical differ-
ences: to detect a difference of 25% in pain (Western
Ontario McMaster Universities Osteoarthritis index
(WOMAC)) with one-tailed testing, a power of 80%, and
alpha 5% (Mean 4.83, SD 2.25 [13]) 55 patients per group
are needed. To detect the same difference in function
(WOMAC) (mean 4.81, SD 2.18 [13]) 51 patients are
needed per group.
As we expect a 20% loss to follow-up, we need to include
150 patients. However, to create options for studying
effect-modification by type and severity of osteoarthritis,
we oversized this trial to 220 patients (110 in each group).
Intervention
Patients who participate in the trial are randomised to
either GS or a placebo for the duration of two years. To
ensure a daily intake of 1500 mg GS, they are required to
take two pills each day. The GS and placebo pills are iden-
tical in taste and appearance and were delivered in identi-
cal plastic bottles. This will ensure true blinding of the
patients and of the researchers. Blinding of the patients
will be tested after two years; if people can guess what sort
of pills they were taking, this might have an influence on
the subjective measures. This will therefore be taken into
account in the analysis of the data.
The Department of Nutritional Sciences at Numico
Research BV manufactured the pills used in this trial.
Randomisation
Following informed consent and baseline assessments,
patients are allocated to the intervention or control group
using a blinded randomisation list. The randomisation
list contains four different strata and is randomised per
block of six numbers. This list was generated with a com-
puter by an independent researcher. This researcher also
handled labelling the pill-bottles with the randomisation
numbers. The researchers involved in this project received
all bottles after they were labelled, ensuring blinding to
treatment allocation. The randomisation list with the key
to treatment allocation will be kept in a safe until the end
of the trial. To be able to perform the analyses blinded, the
allocation to treatment A and treatment B will be pro-
vided, but not the key to A and B.
People are assigned to one of the four different strata on
the basis of the Kellgren-Lawrence score of the hips, knees
and hands. A researcher (RMR) will score all the radio-
graphs according to the Kellgren-Lawrence score. The out-
line of the four different strata is given in table 1. Once the
correct stratum is established at baseline, the patient is
given the subsequent unique four-digit randomisation
number from his/her stratum on the randomisation list.
This number is used for labelling study materials and
data. By stratifying, patients are optimally distributed to
GS and placebo in the different strata, which makes com-
paring people with mild OA to people with moderate-
severe OA, and comparing people with local OA to people
with generalised OA possible. In this way, we will be able
to study whether effect of treatment depends on severity
or localisation of OA.
Measurements
Data for the primary and secondary outcome measures are
being collected at different time-points throughout the
trial. An overview of the timing of the measurements and
the outline of the primary and secondary outcome meas-
ures is given in table 2.
In brief, the trial starts for every patient with a baseline
assessment at the research centre. At the end of this assess-
ment, patients receive a supply of GS or placebo sufficient
for seven months. After the baseline assessment, patients
will receive a questionnaire every three months, which has
to be returned to the researchers, except from those at 6,
12 and 18 months after baseline, which will be collected
by the researchers during a home visit. After two years,
patients return to the research centre for the finalPage 3 of 7
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tion of the outcome measures is described in the follow-
ing sections.
Radiographs
Radiographs are taken during the baseline assessment and
during the final assessment two years later.
At baseline, three anteroposterior (AP) radiographs are
taken, one of the pelvis, one of both knees, and one of
both hands. All radiographs are used to establish what
stratum the subject belongs to (table 1). The radiographs
of hands and knees will not be used to determine out-
come measures and will therefore not be repeated at fol-
low up. As follows from table 1, people with knee and/or
hand OA are stratified to one of the 'generalised OA'
groups (2 or 4).
A highly standardised protocol is used to make the
weight-bearing, AP pelvic radiographs at baseline and fol-
low-up, allowing for a correct measurement of our pri-
mary outcome variable: joint space narrowing. The
patients' feet are positioned alongside a frame, which was
designed to ensure 15° internal rotation of the hips. A
second frame (no internal rotation) is available for
patients with severe mobility restrictions of the hips. The
frame used during the baseline radiograph of a patient
will also be used two years later for his/her follow up radi-
Table 1: Outline of the randomisation strata
Hip radiograph Knee and hand radiographs Type
Group 1 K-L score < 2 K-L score < 2 for hands and knees mild + localised
Group 2 K-L score < 2 K-L score ≥ 2 for hands and/or knees mild + generalised
Group 3 K-L score ≥ 2 K-L score < 2 for hands and knees moderate/severe + localised
Group 4 K-L score ≥ 2 K-L score ≥ 2 for hands and/or knees moderate/severe + generalised
Table 2: Timing of measurements and outline of primary and secondary outcome measures
0 m
B.A.
3 m
Q
6 m
Visit
9 m
Q
12 m
Visit
15 m
Q
18 m
Visit
21 m
Q
24 m
F.A.
Primary outcome measures
Joint space width x x
Pain score (WOMAC) x x
Function score (WOMAC) x x
Secondary outcome measures
Subchondral bone quality x x
Stiffness score (WOMAC) x x x x x x x x x
Quality of life (EuroQol EQ-5D) x x x x x x x x x
Medical consumption x x x x x x x x x
Side effects x x x x x x x x
CTX-II x x x x x
Possible confounders/Effect modifiers
Type of OA (localised – generalised) x
Radiological severity x x
Joint function x x
Age x
Gender x
Activity level x x x x x x x x x
Co-interventions x x x x x x x x x
Compliance (BMQ) x x x x x x x x
Compliance (pill count) x x x x
Note: 0 m: 0 month of follow up, 3 m: 3 months of follow up etc. B.A.: baseline assessment. Visit: 6 monthly visit. F.A.: final assessmentPage 4 of 7
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flexion in hips or knees is recorded. Protocol for the pelvic
X-ray further states that focus-to-film distance should be
130 cm and that the X-ray beam should be centred on the
superior aspect of the pubic symphysis. The X-rays are
digitised.
The X-rays from baseline and final assessment will be ana-
lysed side by side. The minimal joint space width (JSW)
will be identified from the baseline X-ray by assessing four
different points: medial, axial, superior and lateral [14]).
The researcher will also identify a point that appears to be
the minimal JSW. From these five points the actual mini-
mal JSW will be determined. This point will be used to
measure changes in joint space width over the two-year
follow up period.
Dexa-scan
During the baseline and final assessment, a Dual Energy
X-ray Absorptiometry (DEXA) scan will be used to make
scans of the pelvis. A frame similar to the one used for the
radiograph of the hips is also used to make the DEXA-
scan, ensuring 15° internal rotation of the hips. The scan
will be used to study quantitative changes in subchondral
bone density both of the affected joint and of the contra-
lateral joint. Subchondral bone-density alterations might
indicate osteoarthritic progression. This long-term trial
can be helpful to determine whether pre-clinical OA can
be recognised from a DEXA-scan. And, if so, whether GS
prevents the onset or progression of OA in the pre-clinical
stage.
Physical examination
A physical examination is carried out at baseline and is
repeated during the final assessment. At baseline, this test
is first of all used to check part of the inclusion criteria.
Various tests are also carried out to check for co-existing
musculoskeletal disorders. Findings from the physical
examination will be used as baseline characteristics, and
to register clinical signs and joint function after two years
of follow up. Joint function is established by assessing
pain due to joint motion, and by measuring limitation of
joint motion with a two-arm goniometer.
Questionnaires
Throughout the study, patients will fill out a total of nine
questionnaires. The first during the baseline assessment,
followed by a questionnaire every three months in the fol-
lowing two years (including the last one during the final
assessment).
The baseline questionnaire is used to measure different
patient characteristics (age, gender, race, social status,
Body Mass Index (BMI)), disease related characteristics
(localisation of symptoms, duration of symptoms, family
history) and co-morbidities. Of these characteristics, BMI
and co-morbidities will be monitored throughout the
trial.
Three validated instruments are used in all nine question-
naires: the WOMAC questionnaire will be used to estab-
lish severity of clinical status. It contains subscales for
pain, stiffness and function. The WOMAC questionnaire
is extensively validated and recommended for clinical
assessment in osteoarthritis trials by the WHO [15]. The
EuroQol (EQ-5D) will be used to measure quality of life,
because of the usefulness of this scale in cost-effectiveness
analysis [16,17]. The cost-effectiveness analysis will also
be based on employment status, sick leave, changes in
work-tasks or other work-related adjustments, and on
medical consumption. The SQUASH questionnaire is
used to measure load level in work and sports [18].
In the eight follow-up questionnaires, patients will be
asked to answer questions about alterations in their symp-
toms (i.e. whether they improved or deteriorated), which
will be measured with a 7-point Likert scale. Also, compli-
ance to treatment is measured with the Brief Medication
Questionnaire (BMQ) [19].
Laboratory assessments
At baseline, two samples of blood are collected. The first
to measure the erythrocyte sedimentation rate (ESR),
which is used for the inclusion criteria (ACR-criteria). The
second sample is stored at -20°C to create options for
future DNA-research, for which patients gave separate
written informed consent.
Throughout the study, we will collect samples of second-
morning void urine of all patients. In urine a marker of
cartilage degradation can be found, called CTX-II. In the
Rotterdam study [20] this marker was found to be predic-
tive of radiological progression of hip and knee OA. It
may therefore be used to assess the effect of treatment on
the progression of OA. Urine samples will be collected at
baseline and once every six months during follow up. At
the end of the study a total of five samples will be availa-
ble from every patient. These urine samples are stored at -
80°C. If promising new markers are discovered during the
course of the study, these can also be included in the
analysis.
Half-yearly visits
Every six months one of the researchers will visit the
patients at home. The main reason for this visit is to pro-
vide the patient with new pills (sufficient for seven
months). To be able to calculate compliance to treatment,
the pills remaining of the previous supply will be col-
lected. The amount of remaining pills combined with the
score on the compliance questionnaire (BMQ) will give aPage 5 of 7
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has been taking. Finally, a sample of second-morning
void urine on the day of the visit will be collected.
Analyses
The researchers will be aware of allocation to treatment A
or B at the time of the statistical analyses, but will not
know which group received GS and which group received
the placebo. All analyses will take place after the trial has
finished, no intermediate analyses will be performed.
Success of randomisation and normality of outcome
measures will be checked before actual analyses are done.
Differences in the primary outcome measures JSN and
WOMAC (pain and function) between the intervention
and placebo group will be analysed on the basis of the
'intention to treat' principle using linear regression mod-
els. Additionally a per-protocol analysis will be done.
When it turns out that randomisation was (partially)
unsuccessful, we will adjust for differences in prognosis.
Using baseline characteristics, we can identify factors that
influence outcome of the study. Factors that change the
outcome with 10% will be regarded as confounders and
will therefore be added to the regression-model.
A cost-effectiveness analysis will be performed from a
social and a patient perspective, looking at differences in
direct and indirect health care cost between the two
groups (GS and placebo). If the trial does not show a dif-
ference in disease parameters (WOMAC) and quality of
life (EuroQol) between the GS and the placebo group, the
analysis will be reduced to a cost minimisation analysis.
This form of analysis evaluates the efficacy of treatment
based solely on direct and indirect costs. If the study does
find a positive difference in disease parameter and/or
quality of life a cost-effectiveness ratio can be determined
with on the one hand the costs and savings and on the
other hand the disease-specific parameters and also qual-
ity of life.
Current status
A total of 40 GP's were found willing to participate in the
study. They sent a total of 600 letters to inform possible
eligible patients of the study. We received 417 requests for
additional information and thus sent an equal amount of
information folders. Of these 417 people 250 returned a
written informed consent. Eventually 222 people entered
the study. Of the 28 people that did not enter the study,
most did not meet the inclusion criteria and a few people
changed their mind and withdrew their informed consent
before randomisation.
We started including patients at the end of September
2003 and the last patient was included on March 15th of
2004. This means the study will run until March 2006.
The first results will be available around September 2006.
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